Physician profile
Fernando Parawan
NPI 1649377441
$7,916.14
in general payments reported to CMS, 2019-2025
30 companies · $923 in 2025
The $923 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,283 · 2022: $1,436 · 2023: $1,792 · 2024: $1,482 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,197.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,034.66 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $890.45 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbott Laboratories | $887.70 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $739.13 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $627.86 | 2021-2023 | |
| Lilly USA, LLC | $537.30 | 2021-2024 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $450.55 | 2021-2025 | Jardiance, Ofev, Stiolto Respimat |
| Amgen INC. | $377.52 | 2021-2025 | Evenity |
| Pfizer INC. | $347.26 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $330.85 | 2021-2024 | |
| Intuitive Surgical, INC. | $209.99 | 2023-2025 | Da Vinci Surgical System |
| Exact Sciences Corporation | $181.11 | 2023-2024 | Cologuard Collection Kit |
| Cvrx, INC. | $159.13 | 2024 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $155.83 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $129.80 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $125.00 | 2023 | Ycanth |
| Biohaven Pharmaceutical Holding Company LTD. | $125.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $123.47 | 2021 | |
| Astellas Pharma US INC | $118.90 | 2021-2024 | Veozah, Myrbetriq |
| Axsome Therapeutics, INC. | $106.54 | 2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $58.91 | 2021-2022 | |
| Shield Therapeutics INC | $35.85 | 2022 | |
| Merck Sharp & Dohme LLC | $33.55 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $26.24 | 2021 | |
| Sanofi Pasteur INC. | $21.37 | 2021 | |
| Optinose US, INC. | $20.46 | 2021 | |
| Dexcom, INC. | $18.24 | 2024 | Dexcom G6 Transmitter |
| Lifescan, INC. | $17.67 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.13 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Parawan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.